Sigilon picks up $80M to test hemophilia cell therapy in humans

The best treatment for any disease, says Sigilon Therapeutics CEO Rogerio Vivaldi, M.D., is the body’s own cells.

“If we allow cells to do what they are designed to do, that is the best treatment,” Vivaldi told FierceBiotech. These could be islet cells that make insulin in the case of Type 1 diabetes or cells that make clotting factors in the case of hemophilia.